Agios Pharmaceuticals, Inc.: all 52 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia VeraNot yet recruitingNCT07859423Phase 2/3
• A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)RecruitingNCT07656415Phase 3
• A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaRecruitingNCT07517133Phase 3
• A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)RecruitingNCT07506863Phase 3
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaRecruitingNCT07241234Phase 1
• A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationNCT05777993Phase 4
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Active, not recruitingNCT04770779Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Active, not recruitingNCT04770753Phase 3Results posted
• Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007CompletedNCT03853798Phase 3Results posted
• A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaActive, not recruitingNCT03692052Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03559699Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03548220Phase 3Results posted
• A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedNCT02476916Phase 2Results posted
• A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy ParticipantsActive, not recruitingNCT07075640Phase 1
• A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Active, not recruitingNCT06924970Phase 2
• A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy ParticipantsCompletedNCT06745271Phase 1
• Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsCompletedNCT06648824Phase 1
• A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyWithdrawnNCT06286046Phase 2
• Single and Multiple Ascending Dose Study and Food Effect Study for AG181CompletedNCT06286033Phase 1
• A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionCompletedNCT05610657Phase 1
• A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Active, not recruitingNCT05490446Phase 2
• A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05175105Phase 3
• A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodActive, not recruitingNCT05144256Phase 3
• A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Active, not recruitingNCT05031780Phase 2/3
• Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008CompletedNCT04995315
• Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)TerminatedNCT04964323
• A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult ParticipantsCompletedNCT04696393Phase 1
• A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy ParticipantsCompletedNCT04565678Phase 1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell DiseaseCompletedNCT04536792Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsCompletedNCT04472832Phase 1
• A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian ParticipantsCompletedNCT04145128Phase 1
• A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881CompletedNCT04128787Phase 1
• A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy AdultsCompletedNCT04015687Phase 1
• Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult ParticipantsCompletedNCT03991312Phase 1
• A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881CompletedNCT03960502Phase 1
• A Study of AG-636 in the Treatment of Subjects With Advanced LymphomaTerminatedNCT03834584Phase 1
• A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348CompletedNCT03703505Phase 1
• Pyruvate Kinase Deficiency Global Longitudinal RegistryActive, not recruitingNCT03481738
• Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy AdultsCompletedNCT03397329Phase 1
• Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or LymphomaCompletedNCT03361358
• A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic FunctionCompletedNCT03282513Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian OriginCompletedNCT03250598Phase 1
• Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 MutationApproved for marketingNCT03245424
• Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsCompletedNCT03071770Phase 1
• Drug-Drug Interaction Study of AG120 in Healthy SubjectsCompletedNCT02831972Phase 1
• A Safety and Tolerability Study of AG-519 in Healthy SubjectsTerminatedNCT02630927Phase 1
• Food Effect Study of AG120 in Healthy SubjectsCompletedNCT02579707Phase 1
• Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 MutationCompletedNCT02492737Phase 1
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120CompletedNCT02489513Phase 1
• Food Effect Study of AG-221 in Healthy Male SubjectsCompletedNCT02218346Phase 1
• A Phase I Study of AG-348 in Healthy VolunteersCompletedNCT02149966Phase 1
• A Phase I Study of AG-348 in Healthy VolunteersCompletedNCT02108106Phase 1

← Agios Pharmaceuticals, Inc. overview and focus areas